» Articles » PMID: 176581

The Syndromes of Insulin Resistance and Acanthosis Nigricans. Insulin-receptor Disorders in Man

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1976 Apr 1
PMID 176581
Citations 199
Authors
Affiliations
Soon will be listed here.
Abstract

In six patients with acanthosis nigricans variable degrees of glucose intolerance, hyperinsulinemia and marked resistance to exogenous insulin were found. Studies of insulin receptors on circulating monocytes suggest that the insulin resistance in these patients was due to a marked decrease in insulin binding to its membrane receptors. When these patients were fasted, there was a fall in plasma insulin but no increase in insulin binding, suggesting that the receptor defect was not secondary to the hyperinsulinemia. The clinical features shared by these cases and several similar ones previously reported may be divided into two unique clinical syndromes: Type A, a syndrome in younger females with signs of virilization or accelerated growth, in whom the receptor defect may be primary, and Type B, a syndrome in older females with signs of an immunologic disease, in whom circulating antibodies to the insulin receptor are found.

Citing Articles

Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.

Hu C, Chen Y, Yin X, Xu R, Yin C, Wang C Signal Transduct Target Ther. 2025; 10(1):39.

PMID: 39948335 PMC: 11825823. DOI: 10.1038/s41392-024-02098-3.


Conquering diabetes by overcoming psychological barriers and embracing health.

ory F, Kiss B, Zsido A, Teleki S Sci Rep. 2024; 14(1):32104.

PMID: 39738997 PMC: 11686001. DOI: 10.1038/s41598-024-83837-y.


The interplay of factors in metabolic syndrome: understanding its roots and complexity.

Islam M, Wei P, Suzauddula M, Nime I, Feroz F, Acharjee M Mol Med. 2024; 30(1):279.

PMID: 39731011 PMC: 11673706. DOI: 10.1186/s10020-024-01019-y.


Involvement of a battery of investigated genes in lipid droplet pathophysiology and associated comorbidities.

Al Harake S, Abedin Y, Hatoum F, Nassar N, Ali A, Nassar A Adipocyte. 2024; 13(1):2403380.

PMID: 39329369 PMC: 11445895. DOI: 10.1080/21623945.2024.2403380.


A multicenter, open-label, single-arm trial of the long-term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE-02).

Hirota Y, Kakei Y, Imai J, Katagiri H, Ebihara K, Wada J J Diabetes Investig. 2024; 15(9):1211-1219.

PMID: 38702973 PMC: 11363127. DOI: 10.1111/jdi.14226.